Page 21 - Cipla

Goa facility issue worsens Cipla's growth worries; stock falls over 3%

India business has been soft given the realignment of the sales channel

Cipla shareholders approve proposal to raise up to Rs 3,000 crore

In a regulatory filing, Cipla said 99.68% shareholders polled in favour of the resolution to raise funds

Declining India business pulls down Cipla's Q1 growth; US sales grow

Profitability though got a boost with higher contribution from limited competition products in the US

Cipla increases stake in consumer health biz to 100%, looks for tie-ups

The drug maker had set up a separate company with private equity investment in FY2016 to tap the fast growing over the counter medicine portfolio

Active pharmaceutical ingredients focus helps drug firms offset slowdown

Besides captive consumption, the company also supplies APIs to external customers across international markets

As price pressure mounts, pharma companies tap analytics to cut costs

Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution

Cipla urges govt to increase funds, ease policies for domestic pharma firms

In India, the company said it will focus on therapeutic segments like diabetes, dermatology, cardiology and women's health

InvaGen Pharma gets USFDA approval for neuropathic pain management drug

Cipla said the approved product is a generic therapeutic equivalent version of Pfizer's Lyrica

Cipla eyes Chinese respiratory market through JV with Jiangsu Acebright

The JV will set up a manufacturing facility of respiratory products; the plant is expected to be commissioned in 2020

Looking at continued growth across key markets in FY20, says Cipla

Total revenue from operations for the last fiscal stood at Rs 16,362.41 crore. It was Rs 15,219.25 crore in the preceding financial year

Street cautious on Cipla despite healthy March quarter numbers

Higher competitive intensity, increasing investments, and moderate growth could weigh on returns

US court denies Amgen's request for preliminary injunction against Cipla

Preliminary injunction is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order

Margin gain remains a key trigger for Cipla, say analysts

Despite strong domestic growth and improving US prospects, analysts remain sceptical on improvement in profitability in the near-term

Cipla campaign hard-hitting; was aimed at opening people's eyes: Lav Dhruv

We launched the campaign with hoardings showing stark shots of the most polluted places in Delhi, along with a simple message, urging the audience to act quickly before it's too late

Cipla recalls 4,800 bottles of anti-HIV tablets from American market

As per the latest Enforcement Report by the USFDA, the reason for the recall of the bottles is 'failed dissolution specifications'

Cipla to acquire US specialty drugmaker Avenue Therapeutics for Rs 15.6 bn

Acquisition to help the company build a specialty pipeline in the US

Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

The approved products is a generic therapeutic equivalent version of Roche's Valcyte

Cipla shares continue to fall post Q2 results; plunge nearly 6%

At NSE, shares of the company dropped 5.87% to close at Rs 529.95

Cipla hits five-month low on weak outlook; down 12% in two days

The stock was down 5% at Rs 534, trading at its lowest level since June 6, 2018 on the BSE.

Cipla stock falls 7% on weak Q2 results; pressure on tender biz to continue

Company cautious on prospects, given supply disruptions & commodity inflation, among others